Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma

NCT05111574 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05111574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05111574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 11, 2022
Completion date
July 15, 2027
Enrollment
101 (estimated)
Sites
146

Conditions

As the registry lists them; a condition with its own page is linked.

anal melanoma, bladder melanoma, cervical melanoma, esophageal melanoma, gallbladder melanoma, head and neck mucosal melanoma, mucosal melanoma, nasopharyngeal mucosal melanoma, oral cavity mucosal melanoma, penile mucosal melanoma, rectal melanoma, recurrent mucosal melanoma, sinonasal mucosal melanoma, urethral melanoma, urinary system mucosal melanoma, vaginal melanoma, vulvar melanoma